Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

tiated in 2006 and 2007. We expect research and development expenses to trend down in the fourth quarter and into 2009 as we collect clinical data and evaluate each program to determine future clinical direction. At the end of the quarter we reported $27.9 million in cash and short-term investments, which together with anticipated royalty inflows, we believe will fund planned operations for at least the next 12 months."

James S. Burns, EntreMed President and Chief Executive Officer, commented, "We are actively pursuing partners for ENMD-2076 and Panzem(R) RA while continuing our clinical oncology programs, including the Phase 1b dose-escalation study in solid tumors for ENMD-2076. The outcome of our partnering initiatives and anticipated clinical progress will guide our priorities through year-end and into 2009. While we are reducing overall expenses, our clinical trials remain on schedule. We anticipate the presentation of clinical and preclinical data for MKC-1, ENMD-2076 and ENMD-1198 over the next several quarters."

Mr. Burns will present a Company overview at the Rodman & Renshaw 10th Annual Healthcare Conference, which will serve as the Company's third quarter 2008 update. Mr. Burns' presentation is scheduled for 2:25 p.m. (ET) on Tuesday, November 11, 2008 and will be web cast. To access the live presentation, visit the Company's web site at http://www.entremed.com. An archive of the presentation will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... Agricultural firm H.J. Baker & Bro., ... of Tiger-Sul. Since the purchase of Tiger Industries ... May 2005, H.J. Baker has leveraged the innovation of ... comprehensive portfolio of product offerings and solutions expertise. The ... the innovation of Tiger-Sul, transforming the company into a ...
(Date:5/20/2015)... DIEGO , May 20, 2015  Cypher ... announced a collaboration with Celgene Corporation to apply ... genomic biomarkers that associate with patient response to ... is intended to help accelerate patient access to ... efficiencies in clinical research and development and potentially ...
(Date:5/20/2015)... North Carolina , 20. Mai ... Unternehmen für klinische Logistik (Clinical Logistics ... das Geschäftsjahr 2014, das am 31. ... Das Unternehmen hat die Marktentwicklung übertroffen ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... DENVER , May 20, 2015 /PRNewswire/ ... today announced that it is an official ... Management Executives (CHIME) Cooperative Members Services Program. ... of compliant, managed cloud services and best ... of healthcare CIOs and service providers, enabling ...
Breaking Biology Technology:Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3
... cell controlled by a synthetic genome. They now hope to use ... engineer bacteria specially designed to solve environmental or energy problems. ... , at the Science Express website, on Thursday, 20 ... society. The research team, led by Craig Venter of the ...
... , May 20 Dendreon Corporation (Nasdaq: DNDN ) today ... PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, ... Oncology (ASCO) in Chicago on Monday, June 7 at ... , , ...
... May 20 Today, world-renowned scientist Dr. ... at the J. Craig Venter Institute (JCVI) became the first ... news holds groundbreaking potential for solutions to a host of ... cleaning up pollution; creating new energy sources; producing clean water; ...
Cached Biology Technology:Scientists 'boot up' a bacterial cell with a synthetic genome 2Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 4Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting 5Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 2Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 3
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... the latest issue of the journal Emerging Infectious ... the hyperboreal tundra, in connection with the tundra ... These findings indicate that resistance to antibiotics ... prospect for future health care. The scientists ...
... N.Y., JAN. 9, 2008 Not enough American women ... day can help prevent serious birth defects, and only ... essential nutrient beginning before pregnancy, two recent surveys show. ... beginning before pregnancy is crucial because birth defects of ...
... PA (January 11, 2008): Nucleonics, Inc., a ... of novel RNA interference (RNAi)-based therapeutics, announced today ... a Phase 1 human safety study of its ... infection, NUC B1000. NUC B1000 ( ...
Cached Biology News:High degree of resistance to antibiotics in Arctic birds 2New folic acid seal helps women choose enriched grain foods to help prevent birth defects 2New folic acid seal helps women choose enriched grain foods to help prevent birth defects 3Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 3
... allow for the rapid isolation of DNA from ... slice in the spin filter, centrifuge for 3 ... recovered. There is no need to melt agarose ... can also be used for buffer exchange, primer ...
Request Info...
Guinea Pig Complement...
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Biology Products: